Antineoplastic potency of arylchloroethylurea derivatives in murine colon carcinoma

Investigational New Drugs

Volumn 22, Issue 4, 2004, Pages 369-378

  Miot Noirault, Elisabeth ^a   Legault, Jean ^b   Cachin, Florent ^a   Mounetou, Emmanuelle ^a   Degoul, Françoise ^a   Gaudreault, René C ^b   Moins, Nicole ^a   Madelmont, Jean Claude ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

1 aryl 3 (2 chloroethyl)ureas; antitumour activity; CEU 22; CEU 98; experimental colon carcinoma; life span; tubulin

Indexed keywords

CEU 22; CEU 98; FLUOROURACIL; N (4 IODOPHENYL) N' (2 CHLOROETHYL)UREA; N (4 TERT BUTYLPHENYL) N' (2 CHLOROETHYL)UREA; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN CACO 2; CELL STRAIN HT29; CLINICAL PROTOCOL; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; INJECTION; LIFESPAN; MALE; MOUSE; NONHUMAN; OBSERVATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PHENYLUREA COMPOUNDS;

EID: 10244252762     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000036679.12112.4c     Document Type: Article

References (34)

1. Boyle P, Leon ME: Epidemiology of colorectal cancer. Br Med Bull 64: 1-25, 2002
2. Van Cutsem E, Verslype C, Demedts I: The treatment of advanced colorectal cancer: Where are we now and where do we go? Best Pract Res Clin Gastroenterol 16: 319-330, 2002
3. Gaudreault RC, Lacroix J, Page M, Joly LP: Synthesis and in vitro assay of 1-aryl 3-(2-chloroethyl)ureas as potential anticancer agents. J Pharm Sci 77: 185-188, 1988
4. Lacroix JC, Gaudreault RC, Page M, Joly LP: In vitro and in vivo activity of 1-aryl-3-(2-chloroethyl)urea derivatives as new antineoplastic agents. Anticancer Res 8: 595-598, 1988
5. Bechard P, Lacroix J, Poyet P, Gaudreault RC: Synthesis and cytotoxic activity of new alkyl-[3-(2-chloroethyl)ureido]benzene derivatives. Eur J Med Chem 29: 963-966, 1994
6. Mounetou E, Legault J, Lacroix J, Gaudreault RC: Antimitotic antitumor agents: Synthesis, structure-activity relationships, and biological characterization of N-aryl-N′-(2-chloroethyl)ureas as new selective alkylating agents. J Med Chem 44: 694-702, 2001
7. Gaudreault RC, Alaoui-Jamli M, Batist G, Bechard P, Lacroix J, Poyet P: Lack of cross-resistance to a new cytotoxic arylchloroethyl urea in various drug-resistant tumour cells. Cancer Chemoth Pharmacol 33: 489-192, 1994
8. Legault J, Gaulin JF, Mounetou E, Bolduc S, Lacroix J, Poyet P, Gaudreault RC: Microtubule disruption induced in vivo by alkylationof β-tubulinby 1-aryl-3-(2-chloroethyl)ureas, a novel class of soft alkylating agents. Cancer Res 60: 985-992, 2000
9. Maurizis JC, Rapp M, Azim EM, Gaudreault RC, Veyre A, Madelmont JC: Disposition and metabolism of a novel antineoplastic agent, 4-tert-butyl-[3-(2- chloroethyl)ureido]benzene in mice. Drug Metab Dispos 26: 146-151, 1998
10. Boyd MR: The NCI in vitro anticancer drug discovery screen. Concept, implementation, and operation, 1985-1995. Part 1, in vitro methods. In: Humana BT (ed) Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval. Press Inc, Totowa, NJ, 1995, pp. 23-42
11. Boyd MR, Paull FD: Some practical considerations and applications of the national Cancer institute in vitro anticancer drug discovery screen. Drug Dev Res 34: 91-109, 1995
12. O'Brien J, Wilson I, Orton T, Pognan F: Investigation of the Alamar blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267: 5421-5426, 2000
13. Workman P, Twentyman P, balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J: United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (2nd edition) Br J Cancer 77: 1-10, 1998
14. Wilmanns C, Fan D, O'Brian C, Bucana CD, Fidler IJ: Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 52: 98-104, 1992
15. Royce ME, Medgyesy D, Zulowski TH, Dwivedy S, Hoff PM, Pazdur R: Colorectal cancer: Chemotherapy treatment overview. Oncology 14: 40-46, 2000
16. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F: Experimental antitumor activity of Taxotere (RP 56976,NSC 628503), a taxol analogue. Cancer Res 51: 4845-4852, 1991
17. Funahashi Y, Koyanagi N, Kitoh K: Effect of E7010 on liver metastasis and life span of syngeneic C57B1/6 mice bearing orthotopically transplanted murine colon 38 tumour. Cancer Chemother Pharmacol 47: 179-184, 2001
18. Venditti JM: Preclinical drug development: Rationale and methods. Semin Oncol 8: 349-361, 1981
19. Donehower RC, Rowinski EK: Anticancer drugs derived from plants. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancers: Principles and Practice of Oncology. Lippincott Company, 1993, pp. 409-417
20. Jacquesy JC, Fahy J: Cancer: Superacid generation of new antitumour agents. In: Torrence PF (eds) Biochemical Chemistry: Applying Chemical Principles to the Understanding and Treatment of Disease, New York, 2000, pp. 227-246
21. Wilson L, Jordan MA: Microtubule dynamics: Taking aim at a moving target. Chem Biol 2: 569-573, 1995
22. Jordan MA: Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anti-Canc Agents 2: 1-17, 2002
23. Corbett TH, Valeriote FA, Demchik L, Lowichik N, Polin L, Panchapor C, Pugh S, White K, Kushner J, Rake J, Wentland M, Golakoti T, Hetzel C, Ogino J, Patterson G, Moore R: Discovery of cryptophycin-1 and BCN-183577: Examples of strategies and problems in the detection of antitumour activity in mice. Invest New Drugs 15: 207-218, 1997
24. Kobaek-Larsen M, Thorup I, Diederichsen A, Fenger C, Ritskes Hoitinge M: Review of colorectal cancer and its metastases in rodent models: Comparative aspects with those in humans. Comp Med 50(1):16-26, 2000
25. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FR Jr: Tumour induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays with a note on carcinogen structure. Cancer Res 48: 3595-3602, 1975
26. Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D: Systemic treatment of colorectal cancer. Br Med Bull 38: 1000-1015, 2002
27. Mazzolini G, Qian C, Xie X, Sun Y, Lasarte JJ, Drozdzik M, Prieto J: Regression of colon cancer and induction of antitumour immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther 6: 514-522, 1999
28. Morales C, Zurita M, Vaquero J: Growth-inhibiting effects of intralesional docetaxel and paclitaxel on an experimental model of malignant neuroectodermal tumor. J Neurooncol 59: 207-212, 2002
29. Hendriks HR, Plowman J, Berger DP, Paull KD, Fiebig HH, Fodstad O, Dreef-van der Meulen HC, Henrar REC, Pinedo HM, Schwartsmann G: Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent. Ann Oncol 3: 755-763, 1992
30. Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Visalli M, Bisagni E, Pierre A, Atassi G: In vivo antitumour activity of S 16020-2, a new olivacine derivative. Cancer Chemoth Pharmacol 38: 513-521, 1996
31. Nihei Y, Suga Y, Morinaga Y, Ohishi K, Okano A, Ohsumi K, Hatanaka T, Nakagawa R, Tsuji T, Akiyama Y, Saito S, Hori K, Sato Y, Tsuruo T: A novel combrestatin a-4 derivative, AC-7700 shows marked antitumour activity against advanced solit tumours and orthotoipically transplanted tumours. Jpn J Cancer Res 90: 1016-1025, 1999
32. Kerr D: Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. Oncology (Huntingt) 16: 12-15, 2002
33. Twelves C: Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? Oncology (Huntingt) 12: 23-26, 2002.
34. Chau I, Cunningham D: Chemotherapy in colorectal cancer: New options and new challenge. Br Med Bull 64: 159-180, 2002